title: Survival rates of biological therapies for psoriasis treatment in real-world clinical practice: A Canadian multicentre retrospective study.
abstract: OBJECTIVE
  Data on biologic drug survival in real-world psoriasis treatment are limited. There is a need to evaluate long-term trends of biologic use outside the realm of clinical trials.
  
  
  METHODS
  A multicentre chart review was conducted with patients' data from September 2005 to September 2014. Kaplan-Meier plot analysis was used to determine 5-year drug survival rates. A log-rank test was used to compare the rates of drug survival between the studied biologics.
  
  
  RESULTS
  For the 398 patients and 545 treatment series analysed, 1, 2, 3, 4 and 5-year survival rates were 0.826, 0.687, 0.563, 0.475 and 0.420 with etanercept; 0.804, 0.648, 0.553, 0.508 and 0.508 with adalimumab; 0.838, 0.664, 0.554, 0.485 and 0.382 with infliximab; and 0.914, 0.856, 0.800, 0.755 and 0.755 with ustekinumab, respectively. A statistically significant difference was seen between ustekinumab and the other three biologics.
  
  
  CONCLUSIONS
  A progressive decrease in treatment adherence was seen with all four biologics, as expected, but the survival rate of ustekinumab was highest.
authors.affiliation: Department of Health Sciences, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.
authors.forename: Joseph Ec
authors.initials: JE
authors.lastname: Marinas
authors.affiliation: Department of Health Sciences, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.
authors.forename: Whan B
authors.initials: WB
authors.lastname: Kim
authors.affiliation: Department of Medicine, School of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
authors.forename: Ali
authors.initials: A
authors.lastname: Shahbaz
authors.affiliation: Department of Medicine, School of Medicine, University of Toronto, Toronto, Ontario, Canada.
authors.forename: Judy K
authors.initials: JK
authors.lastname: Qiang
authors.affiliation: Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
authors.forename: Simon
authors.initials: S
authors.lastname: Greaves
authors.affiliation: Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.|Department of Dermatology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.|Department of Dermatology, Women's College Hospital, Toronto, Ontario, Canada.
authors.forename: Jensen
authors.initials: J
authors.lastname: Yeung
mesh_terms: D000068879:Adalimumab / Q000627:therapeutic use*; D001688:Biological Products / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000627:therapeutic use*; D000068800:Etanercept / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000069285:Infliximab / Q000627:therapeutic use*; D053208:Kaplan-Meier Estimate; D008297:Male; D017060:Patient Satisfaction; D011565:Psoriasis / Q000188:drug therapy*; D012189:Retrospective Studies; D013997:Time Factors; D000069549:Ustekinumab / Q000627:therapeutic use*; D016903:Drug Monitoring
chemical_list: D001688:Biological Products; D003879:Dermatologic Agents; D000069285:Infliximab; D000069549:Ustekinumab; D000068879:Adalimumab; D000068800:Etanercept
keywords: biological; drug survival; plaque psoriasis